Masaru Shimizu, Hiroshi Noda, Eri Joyashiki, Chie Nakagawa, Kentaro Asanuma, Akira Hayasaka, Motohiro Kato, Masahiko Nanami, Masaki Inada, Chisato Miyaura, Tatsuya Tamura
Parathyroid hormone (PTH) is a potential medicine for osteoporosis, and subcutaneous (s.c.) PTH treatment enhances bone mass; however, continuous infusion of PTH elicits bone resorption and induces bone loss. To clarify this contradictory phenomenon, we examined bone markers and bone mass in rats to assess the optimal duration of PTH(1-34) infusion. Continuous infusion of PTH at 1 µg/kg/h (Css, steady-state concentration ca. 300 pg/mL) for 1-4 h clearly stimulated the expression both of bone formation-related genes (c-fos, Wnt4, EphrinB2) and of bone resorption-related genes (tnfsf11, tnfsf11b, encoding receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG)), but s...
2016: Biological & Pharmaceutical Bulletin